Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have one of these conditions: EGFR-mutated lung cancer (with or without brain metastasis) that has been previously treated, a recurrent high-grade glioma with IDH mutation, or advanced adenoid cystic carcinoma.
- You should have at least one measurable tumor that can be assessed by scans.
- You should be able to perform daily activities with some assistance (ECOG score of 0 to 2).
- You must be able to swallow oral medication.
- You must have adequate organ function (blood, liver, kidneys, and clotting).
- You must be willing to use effective contraception during the study and for 3 months after the last dose.
- You must provide written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication, JBI-778, for people with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The drug aims to stop tumor growth and may offer a treatment option when standard therapies have not worked.
This trial tests a new oral drug, JBI-802, alone or with pembrolizumab, for people with advanced non-small cell lung cancer that has a specific change in the STK11 gene. The goal is to see if this treatment can help shrink tumors or slow their growth.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new NSCLC Patients With EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.